| TNF signaling pathway |
2.69 |
0.00e+0 |
103/112 (91.96%) |
CXCL1;LIF;CCL20;...
|
| Rheumatoid arthritis |
2.58 |
0.00e+0 |
78/93 (83.87%) |
CXCL8;MMP1;CXCL1;...
|
| Legionellosis |
2.48 |
0.00e+0 |
51/57 (89.47%) |
CXCL8;CXCL1;CXCL2;...
|
| Malaria |
2.39 |
0.00e+0 |
44/50 (88%) |
CXCL8;IL6;ICAM1;...
|
| Cytokine-cytokine receptor interaction |
2.37 |
0.00e+0 |
246/295 (83.39%) |
CXCL8;CXCL1;LIF;...
|
| Epithelial cell signaling in Helicobacter pylori infect... |
2.34 |
0.00e+0 |
62/70 (88.57%) |
CXCL8;CXCL1;CXCL2;...
|
| Viral protein interaction with cytokine and cytokine re... |
2.32 |
0.00e+0 |
84/100 (84%) |
CXCL8;CXCL1;TNFSF10;...
|
| ECM-receptor interaction |
2.31 |
0.00e+0 |
80/88 (90.91%) |
LAMC2;SPP1;ITGB5;...
|
| Focal adhesion |
2.30 |
0.00e+0 |
180/201 (89.55%) |
LAMC2;SPP1;ITGB5;...
|
| NF-kappa B signaling pathway |
2.27 |
0.00e+0 |
90/104 (86.54%) |
CXCL8;CXCL1;PLAU;...
|
| Salmonella infection |
2.26 |
0.00e+0 |
198/249 (79.52%) |
CXCL8;TNFSF10;IL6;...
|
| NOD-like receptor signaling pathway |
2.24 |
0.00e+0 |
145/181 (80.11%) |
CXCL8;CXCL1;CXCL2;...
|
| Phagosome |
2.23 |
0.00e+0 |
118/152 (77.63%) |
ITGB5;NCF2;ITGAM;...
|
| Natural killer cell mediated cytotoxicity |
2.20 |
0.00e+0 |
99/131 (75.57%) |
TNFSF10;ICAM1;TNFRSF10B;...
|
| Yersinia infection |
2.19 |
0.00e+0 |
120/137 (87.59%) |
CXCL8;IL6;ARPC1B;...
|
| Pathogenic Escherichia coli infection |
2.19 |
0.00e+0 |
152/197 (77.16%) |
CXCL8;TNFSF10;IL6;...
|
| Shigellosis |
2.14 |
0.00e+0 |
180/246 (73.17%) |
CXCL8;ACTN1;TNIP1;...
|
| Human papillomavirus infection |
2.13 |
0.00e+0 |
284/331 (85.8%) |
LAMC2;SPP1;ITGB5;...
|
| Amoebiasis |
2.13 |
0.00e+0 |
99/102 (97.06%) |
CXCL8;CXCL1;LAMC2;...
|
| T cell receptor signaling pathway |
2.12 |
0.00e+0 |
93/104 (89.42%) |
NFKB1;CDC42;NFKBIA;...
|
| Chagas disease |
2.11 |
0.00e+0 |
93/102 (91.18%) |
CXCL8;IL6;GNAS;...
|
| Toxoplasmosis |
2.11 |
0.00e+0 |
103/112 (91.96%) |
LAMC2;LAMB3;BIRC3;...
|
| Hematopoietic cell lineage |
2.09 |
0.00e+0 |
90/99 (90.91%) |
CD55;CD9;IL6;...
|
| AGE-RAGE signaling pathway in diabetic complications |
2.09 |
0.00e+0 |
97/100 (97%) |
CXCL8;EGR1;IL6;...
|
| Osteoclast differentiation |
2.08 |
0.00e+0 |
117/127 (92.13%) |
FOSL1;RELB;NCF2;...
|
| Small cell lung cancer |
2.07 |
0.00e+0 |
90/92 (97.83%) |
LAMC2;LAMB3;COL4A5;...
|
| Pertussis |
2.07 |
0.00e+0 |
64/76 (84.21%) |
CXCL8;IL6;CXCL5;...
|
| HIF-1 signaling pathway |
2.06 |
0.00e+0 |
105/109 (96.33%) |
IL6;PFKFB3;TIMP1;...
|
| PI3K-Akt signaling pathway |
2.05 |
0.00e+0 |
317/354 (89.55%) |
LAMC2;AREG;SPP1;...
|
| Bladder cancer |
2.05 |
0.00e+0 |
40/41 (97.56%) |
CXCL8;MMP1;MMP9;...
|
| Citrate cycle (TCA cycle) |
-1.61 |
2.27e-2 |
30/30 (100%) |
SDHA;MDH2;SUCLG1;...
|
| Propanoate metabolism |
-1.63 |
2.03e-2 |
30/34 (88.24%) |
ACADS;HIBCH;MLYCD;...
|
| Synthesis and degradation of ketone bodies |
-1.63 |
2.07e-2 |
9/10 (90%) |
HMGCL;ACAT1;ACAT2;...
|
| Fat digestion and absorption |
-1.64 |
1.90e-2 |
35/43 (81.4%) |
NPC1L1;AGPAT1;ACAT1;...
|
| Bile secretion |
-1.65 |
1.78e-2 |
68/90 (75.56%) |
RXRA;ATP1B2;AQP8;...
|
| Histidine metabolism |
-1.66 |
1.65e-2 |
16/22 (72.73%) |
MAOB;ALDH3B1;ALDH1B1;...
|
| beta-Alanine metabolism |
-1.68 |
1.40e-2 |
25/30 (83.33%) |
ALDH3B1;ACADS;HIBCH;...
|
| Primary bile acid biosynthesis |
-1.69 |
1.39e-2 |
15/17 (88.24%) |
AMACR;ACOT8;CYP46A1;...
|
| Ascorbate and aldarate metabolism |
-1.80 |
3.82e-3 |
15/30 (50%) |
UGT2A3;ALDH9A1;ALDH7A1;...
|
| Pentose and glucuronate interconversions |
-1.87 |
2.40e-3 |
17/34 (50%) |
AKR1B1;CRYL1;RPE;...
|
| Pyruvate metabolism |
-1.90 |
1.68e-3 |
41/47 (87.23%) |
ACACB;MDH2;ME1;...
|
| DNA replication |
-1.93 |
1.33e-3 |
34/36 (94.44%) |
MCM6;PRIM2;MCM4;...
|
| Peroxisome |
-1.95 |
4.66e-4 |
72/82 (87.8%) |
ECI2;ACOT8;SOD1;...
|
| Arginine biosynthesis |
-1.97 |
4.94e-4 |
17/22 (77.27%) |
GLS2;GOT1;CPS1;...
|
| Linoleic acid metabolism |
-1.98 |
5.25e-4 |
21/29 (72.41%) |
CYP2C19;PLA2G4A;PLA2G12A;...
|
| Fanconi anemia pathway |
-2.04 |
5.60e-4 |
36/54 (66.67%) |
BRIP1;PALB2;RPA3;...
|
| Cysteine and methionine metabolism |
-2.08 |
6.00e-4 |
43/50 (86%) |
GCLC;MPST;TST;...
|
| Drug metabolism |
-2.09 |
6.46e-4 |
78/151 (51.66%) |
DPYS;FMO4;GSTA4;...
|
| Butanoate metabolism |
-2.09 |
7.00e-4 |
23/28 (82.14%) |
HMGCL;ACAT1;ACAT2;...
|
| Fatty acid degradation |
-2.11 |
7.63e-4 |
40/43 (93.02%) |
ALDH9A1;ACAT1;HADHB;...
|
| Ribosome |
-2.14 |
8.39e-4 |
113/158 (71.52%) |
RPS3;RPS10;RPL32;...
|
| Valine, leucine and isoleucine degradation |
-2.17 |
0.00e+0 |
42/48 (87.5%) |
PCCA;BCKDHB;BCKDHA;...
|
| Tryptophan metabolism |
-2.18 |
0.00e+0 |
35/42 (83.33%) |
AOC1;ALDH9A1;ACAT1;...
|
| Glycine, serine and threonine metabolism |
-2.21 |
0.00e+0 |
31/40 (77.5%) |
SHMT1;ALDH7A1;AGXT;...
|
| Alanine, aspartate and glutamate metabolism |
-2.24 |
0.00e+0 |
27/37 (72.97%) |
ALDH4A1;AGXT;ALDH5A1;...
|
| Retinol metabolism |
-2.38 |
0.00e+0 |
41/68 (60.29%) |
CYP2C18;ADH6;ADH5;...
|
| Glyoxylate and dicarboxylate metabolism |
-2.39 |
0.00e+0 |
23/30 (76.67%) |
MDH2;PCCA;ACAT1;...
|
| Tyrosine metabolism |
-2.42 |
0.00e+0 |
30/36 (83.33%) |
COMT;FAH;DCT;...
|
| Steroid hormone biosynthesis |
-2.48 |
0.00e+0 |
43/61 (70.49%) |
AKR1D1;COMT;HSD17B2;...
|
| Metabolism of xenobiotics by cytochrome P450 |
-2.52 |
0.00e+0 |
49/77 (63.64%) |
GSTA4;CYP2D6;ADH6;...
|
